TD Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-242,044
| Closed | -$9.61M | – | 1237 |
|
|
2026
Q1 | $9.61M | Sell |
242,044
-134,300
| -36% | -$3.44M | 0.01% | 654 |
|
|
2025
Q4 | $9.41M | Sell |
376,344
-90,616
| -19% | -$2.3M | 0.01% | 675 |
|
|
2025
Q3 | $11.3M | Sell |
466,960
-86,332
| -16% | -$1.53M | 0.01% | 628 |
|
|
2025
Q2 | $7.27M | Sell |
553,292
-34,830
| -6% | -$441K | 0.01% | 708 |
|
|
2025
Q1 | $8.46M | Sell |
588,122
-53,592
| -8% | -$877K | 0.01% | 678 |
|
|
2024
Q4 | $10.7M | Buy |
641,714
+83,000
| +15% | +$1.37M | 0.01% | 638 |
|
|
2024
Q3 | $8.82M | Buy |
558,714
+237,546
| +74% | +$2.91M | 0.01% | 670 |
|
|
2024
Q2 | $2.9M | Buy |
321,168
+92,524
| +40% | +$878K | ﹤0.01% | 885 |
|
|
2024
Q1 | $2.58M | Buy |
228,644
+42,334
| +23% | +$401K | ﹤0.01% | 939 |
|
|
2023
Q4 | $1.48M | Hold |
186,310
| – | – | ﹤0.01% | 1093 |
|
|
2023
Q3 | $1.21M | Buy |
186,310
+104,255
| +127% | +$713K | ﹤0.01% | 1102 |
|
|
2023
Q2 | $508K | Hold |
82,055
| – | – | ﹤0.01% | 1264 |
|
|
2023
Q1 | $316K | Hold |
82,055
| – | – | ﹤0.01% | 1336 |
|
|
2022
Q4 | $254K | Hold |
82,055
| – | – | ﹤0.01% | 1374 |
|
|
2022
Q3 | $349K | Hold |
82,055
| – | – | ﹤0.01% | 1351 |
|
|
2022
Q2 | $400K | Buy |
82,055
+48,803
| +147% | +$312K | ﹤0.01% | 1322 |
|
|
2022
Q1 | $298K | Hold |
33,252
| – | – | ﹤0.01% | 1396 |
|
|
2021
Q4 | $374K | Hold |
33,252
| – | – | ﹤0.01% | 1411 |
|
|
2021
Q3 | $555K | Hold |
33,252
| – | – | ﹤0.01% | 1369 |
|
|
2021
Q2 | $686K | Buy |
+33,252
| New | +$781K | ﹤0.01% | 1345 |
|
TD Asset Management's CNTA Position: Q2 2026 in Review
TD Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 242,044 shares — an estimated $9.61M sold.
TD Asset Management first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $11.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- TD Asset Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- TD Asset Management sold 242,044 Centessa Pharmaceuticals shares in Q2 2026, an estimated $9.61M.
- TD Asset Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- TD Asset Management's Centessa Pharmaceuticals position peaked at $11.3M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.